initi coverag
find alpha still possibl target
therapi portfolio
non-u analyst us disclosur credit suiss seek busi compani cover research report result investor awar firm may
conflict interest could affect object report investor consid report singl factor make invest decis
charl martineau univers toronto lc stock recov highs/low late
earli investor seem cautiou approach
factset consensu valuat multipl forward p/e larg cap biotech set
sentiment around larg cap seem poor concern drug price growth recent phase failur
sentiment around smid cap better specialist posit around catalyst
valuat still rel near all-tim high acquisit premium higher ever good smid cap
charl martineau univers toronto coverag univers glanc
consensu
vertex differenti growth profil expect drive near-term cash flow also allow reinvest busi
support long-term growth think continu commerci execut pipelin updat guidanc revis support share
rel peer expect updat file full data set tripl combin therapi well continu progress toward
reimburs uk franc rest world drive upsid
proprietari work support thesi separ model uk franc opportun scenario analysi
neurocrin commercial-stag biotechnolog compani two market asset ingrezza tardiv dyskinesia td orilissa
endometriosi em market partner think ingrezza best-in-class treatment td expect drive revenu
earn growth next year see underappreci upsid potenti pipelin focus central nervou system
asset parkinson diseas opicapon gene therapi congenit adren hyperplasia among smid-cap coverag neurocrin
top pick due project strong revenu growth name ingrezza addit revenu stream orilissa solid pipelin favor
risk/reward proprietari work support thesi support expert physician discuss
view attract rel peer underappreci biosimilar busi could help chang project base busi
revenu declin rel stabil vs large-cap peer vari promis pipelin novel asset oncolog immunolog
compel valuat good balanc return capit sharehold repurchas dividend pipelin potenti abil yet
urgent need proprietari work support thesi asthma physician survey
aimmun current leader treatment peanut allergi late-st asset believ oral immunotherapi
like approv therapi reduc risk accident exposur children adult peanut allergi competitor aimmun
dbv least one year behind follow voluntari withdraw bla competit product viaskin peanut decemb
overal expect share continu outperform get closer launch expect late earli beyond
peanut allergi aimmun also pursu develop treatment egg allergi
neutral rate predic three main issu like base hiv busi see outsiz growth would significantli alter
earn project cell-therapi import platform sale yescarta unlik gener revenu akin sovaldi/harvoni
unlik under-perform think forward price-to-earnings multipl somewhat protect contract howev new
strateg vision acquisit could see expans
proprietari work support thesi hiv physician survey
begun find way back pipelin execut failur epacadostat howev need clinic evid trial
execut pipelin posit stock like jakafi franchis revenu growth profil see opportun fairli
valu find difficult point specif pipelin asset high convict clinic commerci perspect rel
smid-cap peer rate neutral think better pipelin risk/reward commerci busi upsid elsewher
whole view current valuat busi fair like compani focu innov expans pipelin
concern eylea could face increas headwind upcom launch novarti brolucizumab consensu forecast sanofi
collabor may high estim seem overst collabor profit
proprietari work support thesi asthma physician survey
life beyond aducanumab like remain challeng base busi like declin near term weak pipelin
like abl yield revenu earn growth ms expect increasingli competit major spinraza revenu
risk competit anticip signific share loss new sma spinal muscular atrophi incid novarti zolgensma long-term
believ ptc/roch risdiplam could take signific share preval sma market alzheim longer around focu investor
attent base busi eros like drive downsid manag priorit share repurchas could lead
multipl compress
proprietari work support thesi ms physician survey illustr scenario analysi spinraza franchis scenario analysi
charl martineau univers toronto target therapi roadmap find alpha
break compani three area analysi
charl martineau univers toronto re-cap what launch report
launch coverag larg cap biotech name
outperform amgen aimmun assumpt coverag
under-perform consensu call
posit sector think investor thought select stock
larg cap sentiment remain poor concern growth drug price recent phase failur
catalyst-driven smid cap stock favor specialist investor
think stock select alpha gener target therapi
examin state commerci busi
 like remain backdrop sector
fda new leadership see continu product measur drug approv innov
drug price overhang us elect potenti reform medicar part
allergy/immunolog novel oncolog neurosci migrain genom manipul
compani mention price aimt oq inc amgn oq inc biib oq gilead scienc inc gild oq incyt corpor inci oq mylan inc myl oq inc nbix oq novarti novn regeneron pharmaceut inc regn oq roch rog sanofi sasi pa inc vrtx oq disclosur appendix analyst certif evan seigerman certifi view express report accur reflect person view subject compani secur part compens directli indirectli relat specif recommend view express report decemb analyst stock rate defin follow outperform stock total return expect outperform relev benchmark next month neutral stock total return expect line relev benchmark next month under-perform stock total return expect under-perform relev benchmark next month relev benchmark region decemb japanes rate base stock total return rel analyst coverag univers consist compani cover analyst within relev sector outperform repres attract neutral less attract underperform least attract invest opportun octob canadian well european rate base stock total return rel analyst coverag univers consist compani cover analyst within relev sector outperform repres attract neutral less attract underperform least attract invest opportun latin american asia stock exclud japan australia rate base stock total return rel averag total return relev countri region benchmark india bse sensex index prior octob canadian rate base stock absolut total return potenti current share price rel attract stock total return potenti within analyst coverag univers australian new zealand stock expect total return calcul includ roll dividend yield outperform rate assign greater equal under-perform less equal neutral may assign overlap rate rang allow analyst assign rate put context associ risk prior may rang outperform under-perform rate overlap neutral threshold oper juli restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun includ invest recommend cours credit suiss engag invest bank transact certain circumst rate nr credit suiss equiti research invest rate view stock secur relat compani time cover nc credit suiss equiti research provid on-going coverag compani offer invest rate invest view equiti secur compani relat product volatil indic stock defin volatil stock price move month least past month analyst expect signific volatil go forward analyst sector weight distinct analyst stock rate base analyst expect fundament and/or valuat sector rel group histor fundament and/or valuat overweight analyst expect sector fundament and/or valuat favor next month market weight analyst expect sector fundament and/or valuat neutral next month underweight analyst expect sector fundament and/or valuat cautiou next month analyst coverag sector consist compani cover analyst within relev sector analyst may cover multipl sector credit suiss distribut stock rate bank client global rate distribut rate versu univers bank client outperform/buy bank client neutral/hold bank client underperform/sel bank client restrict purpos nyse finra rate distribut disclosur requir stock rate outperform neutral under-perform close correspond buy hold sell respect howev mean stock rate determin rel basi pleas refer definit investor decis buy sell secur base invest object current hold individu factor import global disclosur credit suiss research report made avail client proprietari research portal cs credit suiss research product may also made avail third-parti vendor altern electron mean conveni certain research product made avail cs servic provid credit suiss analyst client may depend specif client prefer regard frequenc manner receiv commun client risk profil invest size scope overal client relationship firm well legal regulatori constraint access credit suiss research entitl receiv time manner pleas contact sale repres go http //plu credit-suiss com credit suiss polici updat research report deem appropri base develop subject compani sector market may materi impact research view opinion state herein credit suiss polici publish invest research imparti independ clear fair mislead detail pleas refer credit suiss polici manag conflict interest connect invest research http //www credit-suiss com/sites/disclaimers-ib/en/managing-conflict html inform relat tax statu financi instrument discuss herein intend provid tax advic use anyon provid tax advic investor urg seek tax advic base particular circumst independ tax profession credit suiss decid enter busi relationship compani credit suiss determin involv develop manufactur acquisit anti-personnel mine cluster munit credit suiss posit issu pleas see http //www credit-suiss com/media/assets/corporate/docs/about-us/responsibility/banking/policy-summaries-en pdf analyst respons prepar research report receiv compens base upon variou factor includ credit suiss total revenu portion gener credit suiss invest bank activ compani mention section full compani name credit suiss current within past month follow invest bank client amgn oq biib oq credit suiss provid invest bank servic subject compani amgn oq biib oq within past month within last month credit suiss receiv compens non-invest bank servic product follow issuer amgn oq within past month credit suiss receiv compens invest bank servic follow issuer amgn oq credit suiss expect receiv intend seek invest bank relat compens subject compani inci oq aimt oq amgn oq biib oq within next month credit suiss current within past month follow issuer client servic provid non-investment-bank securities-rel amgn oq credit suiss current within past month follow issuer client servic provid non-investment-bank non securities-rel amgn oq credit suiss member credit suiss group market maker liquid provid secur follow subject issuer aimt oq amgn oq biib oq gild oq inci oq nbix oq regn oq vrtx oq member credit suiss group parti agreement may provid servic set section annex direct european parliament council mifid servic subject issuer amgn oq biib oq within past month date time product dissemin histori recommend subject compani featur report dissemin within past month pleas refer link import region disclosur singapor recipi contact credit suiss ag singapor branch matter aris research report analyst involv prepar report may particip event host subject compani includ site visit credit suiss accept permit analyst accept payment reimburs travel expens associ event credit suiss secur canada inc polici procedur regard dissemin equiti research pleas visit http //www credit-suiss com/sites/disclaimers-ib/en/canada-research-polici html investor note incom secur financi instrument may fluctuat price valu secur instrument may rise fall case investor may lose entir princip invest research report author credit suiss secur usa llc evan seigerman import credit suiss holt disclosur holt methodolog assign rate target price secur analyt tool involv use set proprietari quantit algorithm warrant valu calcul collect call holt valuat model consist appli compani includ databas third-parti data includ consensu earn estim systemat translat number default variabl incorpor algorithm avail holt valuat model sourc financi statement price earn data provid outsid data vendor subject qualiti control may also adjust close measur underli econom firm perform adjust provid consist analyz singl compani across time analyz multipl compani across industri nation border default scenario produc holt valuat model establish warrant price secur third-parti data updat warrant price may also chang default variabl may also adjust produc altern warrant price could occur warrant price algorithm output appli systemat across compani base histor level volatil return addit inform holt methodolog avail request cfroi cfroe holt holt len holtfolio clariti confid power holt trademark regist trademark credit suiss group ag affili unit state countri holt corpor perform valuat advisori servic credit suiss credit suiss group ag subsidiari affili right reserv import disclosur regard compani subject report avail call import disclosur except valuat methodolog risk discuss also avail credit suiss disclosur websit charl martineau univers toronto may
